Fig. 4
From: Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study
Current status of comorbidity by HAE prophylaxis taken. *Note: Low base. **Mean scores were significantly higher among patients currently on C1-INH compared to those on other HAE prophylaxis treatments (3.7 vs. 3.1). ***The study was not designed nor powered to detect a link between C1-inh and comorbidities. Other Prophylaxis treatments include: lanadelumab, danazol, tranexamic acid, icatibant, and other prophylaxis treatments